The HER2-positive breast cancer cell lines wereclassified as trastuzumab-sensitive or trastuzumab-refractory based on the data from the literature.We then compared the normalized expression data for ATG12 amongtrastuzumab-sensitive (blue dots in Fig. 2)and trastuzumab-refractory (red dots in Fig. 2) cell lines. This evidence concerns the gene ATG12 and breast carcinoma.